logo

Clinical Trial Results

Share

Shares of Co-Diagnostics Inc. (CODX) are up over 79%, following news that the Company has completed the principle design work for a PCR screening test for new coronavirus, 2019-nCoV, intended to address potential need for detection of the virus.

Genentech, a member of the Roche Group (RHHBY), said that its Risdiplam met primary endpoint in pivotal firefish trial in infants with type 1 spinal muscular atrophy. Risdiplam demonstrated statistically significant and medically meaningful motor milestone improvement in infants with Type 1 spinal...

frequncy-jan22.jpg Shares of Frequency Therapeutics Inc. (FREQ) which closed at a new high of $26, have gained 50 percent over the last 1 month.

novavax-jan21.jpg Shares of Novavax Inc. (NVAX) have gained more than 46% over the last 5 trading days, thanks to positive development related to its NanoFlu vaccine.

fortyseven-jan20.jpg Shares of Forty Seven Inc. (FTSV) have been on a roll ever since the Company presented updated clinical data from its ongoing phase Ib trial evaluating Magrolimab in combination with Azacitidine for the treatment of myelodysplastic syndrome and acute myeloid leukemia last December.

pharma-071117_18jan20.jpg Shares of Bellicum Pharmaceuticals Inc. (BLCM) have gained more than 140% over the last 1 month as the Company gears up to present new data related to its autologous GoCAR-T product candidate BPX-601.

rapttherapeutics-jan16.jpg Shares of RAPT Therapeutics Inc. (RAPT) have gained nearly 29 percent over the last five trading days as the Company gears up for some near-term clinical milestones.

AbbVie (ABBV) said that new head-to-head phase 3 data show skyrizi superior to cosentyx across primary and all ranked secondary endpoints in adults with moderate to severe plaque psoriasis at 52 weeks. Of patients treated with skyrizi, 87 percent achieved PASI 90 compared to 57 percent of Cosentyx-treated...

Acasti Pharma Inc. (ACST) reported topline results from its phase 3 TRILOGY 1 trial for the lead product candidate, CaPre, being developed to treat severe hypertriglyceridemia. In the study, both the placebo and CaPre study groups experienced significant reductions in triglycerides within the first four...

Oyster Point Pharma Inc. (OYS) said that its OC-01 Nasal Spray met primary endpoint in Phase 2 Mystic Trial in subjects with Dry Eye disease. OC-01 nasal spray showed a statistically significant improvement in Schirmer's score at Day 84 in both doses tested compared to control. OC-01 nasal spray is...

veronapharma-dec27.jpg Verona Pharma plc (VRNA) is all set to announce results from its phase IIb dose-ranging study evaluating nebulized Ensifentrine as an add-on to treatment with a long-acting bronchodilator in patients with moderate-to-severe chronic obstructive pulmonary disease on Monday, January 13, 2020, at 5.00 am GMT.

turningpointtherapeutics-jan09.jpg Turning Point Therapeutics, Inc. (TPTX) jumped to a new high of $65.94, in Wednesday's intra-day trading session, before closing at $64.30. The stock debuted on the Nasdaq on April 17, 2019, at an opening price of $24.25.

dermira-jan09.jpg Shares of Dermira, Inc. (DERM) hit a new high of $19.30 on Wednesday's trading before closing at $17.56. The stock is up nearly 140% year-to-date.

appliedtherapeutics-jan09.jpg Shares of Applied Therapeutics Inc. (APLT) touched an all-time high of $40.14 in intraday trading on Wednesday, a gain of over 50% from the previous day's close, thanks to the Company's positive phase II Galactosemia study results.

prevail-jan08.jpg Shares of Prevail Therapeutics Inc. (PRVL) have gained more than 75% over the last three months, thanks to the progress on its pipeline of AAV-based gene therapies for patients with neurodegenerative disorders.

Follow RTT
>